BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 17149857)

  • 1. Interpreting steep dose-response curves in early inhibitor discovery.
    Shoichet BK
    J Med Chem; 2006 Dec; 49(25):7274-7. PubMed ID: 17149857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of detergent on "promiscuous" inhibitors.
    Ryan AJ; Gray NM; Lowe PN; Chung CW
    J Med Chem; 2003 Jul; 46(16):3448-51. PubMed ID: 12877581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aggregator compounds confound amyloid fibrillization assay.
    Rishton GM
    Nat Chem Biol; 2008 Mar; 4(3):159-60. PubMed ID: 18277973
    [No Abstract]   [Full Text] [Related]  

  • 4. Small-molecule aggregates inhibit amyloid polymerization.
    Feng BY; Toyama BH; Wille H; Colby DW; Collins SR; May BC; Prusiner SB; Weissman J; Shoichet BK
    Nat Chem Biol; 2008 Mar; 4(3):197-9. PubMed ID: 18223646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promiscuous aggregate-based inhibitors promote enzyme unfolding.
    Coan KE; Maltby DA; Burlingame AL; Shoichet BK
    J Med Chem; 2009 Apr; 52(7):2067-75. PubMed ID: 19281222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening in a spirit haunted world.
    Shoichet BK
    Drug Discov Today; 2006 Jul; 11(13-14):607-15. PubMed ID: 16793529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A high-throughput screen for aggregation-based inhibition in a large compound library.
    Feng BY; Simeonov A; Jadhav A; Babaoglu K; Inglese J; Shoichet BK; Austin CP
    J Med Chem; 2007 May; 50(10):2385-90. PubMed ID: 17447748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stability and equilibria of promiscuous aggregates in high protein milieus.
    Coan KE; Shoichet BK
    Mol Biosyst; 2007 Mar; 3(3):208-13. PubMed ID: 17308667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. O-aryloxycarbonyl hydroxamates: new beta-lactamase inhibitors that cross-link the active site.
    Wyrembak PN; Babaoglu K; Pelto RB; Shoichet BK; Pratt RF
    J Am Chem Soc; 2007 Aug; 129(31):9548-9. PubMed ID: 17628063
    [No Abstract]   [Full Text] [Related]  

  • 10. Discovery of novel lipophilic inhibitors of OXA-10 enzyme (class D beta-lactamase) by screening amino analogs and homologs of citrate and isocitrate.
    Beck J; Vercheval L; Bebrone C; Herteg-Fernea A; Lassaux P; Marchand-Brynaert J
    Bioorg Med Chem Lett; 2009 Jul; 19(13):3593-7. PubMed ID: 19467869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IRT and CMT beta-lactamases and inhibitor resistance.
    Cantón R; Morosini MI; de la Maza OM; de la Pedrosa EG
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():53-62. PubMed ID: 18154528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practical robust fit of enzyme inhibition data.
    Kuzmic P; Hill C; Janc JW
    Methods Enzymol; 2004; 383():366-81. PubMed ID: 15063658
    [No Abstract]   [Full Text] [Related]  

  • 13. Inhibition of serine beta-lactamases by vanadate-catechol complexes.
    Adediran SA; Pratt RF
    Biochemistry; 2008 Sep; 47(36):9467-74. PubMed ID: 18702503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process.
    Watanabe A; Nakamura K; Okudaira N; Okazaki O; Sudo K
    Drug Metab Dispos; 2007 Jul; 35(7):1232-8. PubMed ID: 17392390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal design for the dose-response screening of tight-binding enzyme inhibitors.
    Kuzmič P
    Anal Biochem; 2011 Dec; 419(2):117-22. PubMed ID: 21871865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural insights into the design of inhibitors for the L1 metallo-beta-lactamase from Stenotrophomonas maltophilia.
    Nauton L; Kahn R; Garau G; Hernandez JF; Dideberg O
    J Mol Biol; 2008 Jan; 375(1):257-69. PubMed ID: 17999929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined mass spectrometry and dynamic chemistry approach to identify metalloenzyme inhibitors.
    Liénard BM; Selevsek N; Oldham NJ; Schofield CJ
    ChemMedChem; 2007 Feb; 2(2):175-9. PubMed ID: 17206734
    [No Abstract]   [Full Text] [Related]  

  • 18. Identification of potential glycogen kinase-3 inhibitors by structure based virtual screening.
    Dessalew N; Bharatam PV
    Biophys Chem; 2007 Jul; 128(2-3):165-75. PubMed ID: 17482749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural basis for the broad-spectrum inhibition of metallo-beta-lactamases by thiols.
    Liénard BM; Garau G; Horsfall L; Karsisiotis AI; Damblon C; Lassaux P; Papamicael C; Roberts GC; Galleni M; Dideberg O; Frère JM; Schofield CJ
    Org Biomol Chem; 2008 Jul; 6(13):2282-94. PubMed ID: 18563261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of aminoheterocycles as a novel beta-secretase inhibitor class: pH dependence on binding activity part 1.
    Stachel SJ; Coburn CA; Rush D; Jones KL; Zhu H; Rajapakse H; Graham SL; Simon A; Katharine Holloway M; Allison TJ; Munshi SK; Espeseth AS; Zuck P; Colussi D; Wolfe A; Pietrak BL; Lai MT; Vacca JP
    Bioorg Med Chem Lett; 2009 Jun; 19(11):2977-80. PubMed ID: 19409780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.